Further, in a mouse model of small-cell lung cancer (SCLC), co-administration of anti-VEGF and anti-PD-L1 mAbs resulted in a more prominent therapeutic outcome than mono therapy with each agent [107]. This evidence concerns the gene CD274 and small cell lung carcinoma.